Citigroup’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Citigroup’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,000	Closed	-$4K	–	6863
2022 Q1	$4K	Buy	+6,000	New	+$4.05K	﹤0.01%	5933

Other funds holding MITO

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citigroup's MITO Position: Q2 2022 in Review

Citigroup sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q2 2022, closing a stake of 6,000 shares — an estimated $4K sold.

Citigroup first reported a position in MITO in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 19 funds tracked by Wall St. Rank hold MITO as of Q2 2022.

Citigroup reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q2 2022 after selling out during the quarter.
Citigroup sold 6,000 Stealth BioTherapeutics Corp. ADS shares in Q2 2022, an estimated $4K.
Citigroup first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2022 and held it in 1 quarter.
Citigroup's Stealth BioTherapeutics Corp. ADS position peaked at $4K in Q1 2022.
19 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.